Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,096 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Borderline resectable pancreatic cancer: More than an anatomical concept.
Petrelli F, Inno A, Barni S, Ghidini A, Labianca R, Falconi M, Reni M, Cascinu S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente) and San Raffaele Hospital. Petrelli F, et al. Among authors: falconi m. Dig Liver Dis. 2017 Feb;49(2):223-226. doi: 10.1016/j.dld.2016.11.010. Epub 2016 Dec 5. Dig Liver Dis. 2017. PMID: 27931968
Resectable pancreatic cancer: who really benefits from resection?
Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, Pederzoli P, Falconi M. Barugola G, et al. Among authors: falconi m. Ann Surg Oncol. 2009 Dec;16(12):3316-22. doi: 10.1245/s10434-009-0670-7. Ann Surg Oncol. 2009. PMID: 19707831
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pederzoli P, Falconi M. Reni M, et al. Among authors: falconi m. Anticancer Drugs. 2010 Apr;21(4):459-64. doi: 10.1097/CAD.0b013e328336f50e. Anticancer Drugs. 2010. PMID: 20110805
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Colucci G, et al. Among authors: falconi m. J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194854 Clinical Trial.
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Reni M, Pasetto LM, Passardi A, Milella M, Mambrini A, Cereda S, Aprile G, Tronconi MC, Berardi R, Cordio S, Sartori N, Rognone A, Pederzoli P, Falconi M. Reni M, et al. Among authors: falconi m. Dig Liver Dis. 2011 Mar;43(3):225-30. doi: 10.1016/j.dld.2010.09.010. Epub 2010 Nov 2. Dig Liver Dis. 2011. PMID: 21044873
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Santoni M, et al. Among authors: falconi m. Cancer Metastasis Rev. 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5. Cancer Metastasis Rev. 2014. PMID: 24337954 Review.
1,096 results